Shots:
- Cheplapharm to pay AstraZeneca a total of $400M non-contingent consideration, present value recognised as other operating income upon completion of the transaction, anticipated during the Q4’2020. $250M (of the $400M consideration) will be payable on completion and the remainder in H1’2021
- AstraZeneca has agreed to sell the commercial rights to Atacand (candesartan cilexetil) and Atacand Plus (candesartan cilexetil + hydrochlorothiazide) in around 70 countries globally to Cheplapharm
- Atacand is a selective, AT1 subtype angiotensin II receptor antagonist that is indicated for the management of hypertension in adults and children/adolescents, as well as HF in adults
Click here to read the full press release/ article | Ref: AstraZeneca | Image: Financial Times
The post AstraZenca Expands Supply Agreement with Cheplapharm for Atacand (candesartan cilexetil) and Atacand Plus (candesartan cilexetil + hydrochlorothiazide) to Cheplapharm first appeared on PharmaShots.
